In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
There are nearly too many surging sectors to count.
Check out GSK's well developed base pattern.
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.